Number of the records: 1
rádioimunoterapia
SYS d016499 LBL 00000nz--a2200000o--4500 005 20250606214636.9 008 920502|||anznnbabn-----------|-a|a------ 040 $b slo $a DNLM $d BA006 065 $a E02.095.465.425.750 065 $a E02.186.750 065 $a E02.815.520 066 $a 01 $c 03 150 $a rádioimunoterapia $x AE $x CL $x EC $x ES $x HI $x IS $x MO $x MT $x NU $x PX $x SN $x ST $x TD $x VE $2 slo 550 $7 sllk_us_auth*d018033 $Y Antibodies, Bispecific $w b $a protilátky bišpecifické 665 $a 92 $2 eng 665 $a Antibodies, Monoclonal/therapeutic use (1984-1991) $2 eng 665 $a Immunotherapy (1984-1991) $2 eng 665 $a specific radioisotope/therapeutic use (1981-1991) $2 eng 680 9-
$i Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY). $2 eng 680 $a coordinate with disease /radiother $2 eng 750 -2
$a Radioimmunotherapy $2 eng 980 $x M
Number of the records: 1